Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study

Stefan Wolking*, Herbert Schulz, Anne T. Nies, Mark Mccormack, Elke Schaeffeler, Pauls Auce, Andreja Avbersek, Felicitas Becker, Karl M. Klein, Martin Krenn, Rikke S. Møller, Marina Nikanorova, Sarah Weckhuysen, Gianpiero L. Cavalleri, Norman Delanty, Chantal Depondt, Michael R. Johnson, Bobby P.C. Koeleman, Wolfram S. Kunz, Anthony G. MarsonJosemir W. Sander, Graeme J. Sills, Pasquale Striano, Federico Zara, Fritz Zimprich, Yvonne G. Weber, Roland Krause, Sanjay Sisodiya, Matthias Schwab, Thomas Sander, Holger Lerche, EpiPGX Consortium

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstrakt

Aim: Pharmacoresistance is a major burden in epilepsy treatment. We aimed to identify genetic biomarkers in response to specific antiepileptic drugs (AEDs) in genetic generalized epilepsies (GGE). Materials & methods: We conducted a genome-wide association study (GWAS) of 3.3 million autosomal SNPs in 893 European subjects with GGE - responsive or nonresponsive to lamotrigine, levetiracetam and valproic acid. Results: Our GWAS of AED response revealed suggestive evidence for association at 29 genomic loci (p <10-5) but no significant association reflecting its limited power. The suggestive associations highlight candidate genes that are implicated in epileptogenesis and neurodevelopment. Conclusion: This first GWAS of AED response in GGE provides a comprehensive reference of SNP associations for hypothesis-driven candidate gene analyses in upcoming pharmacogenetic studies.

OriginalsprogEngelsk
TidsskriftPharmacogenomics
Vol/bind21
Udgave nummer5
Sider (fra-til)325-335
ISSN1462-2416
DOI
StatusUdgivet - 14. apr. 2020

Fingeraftryk Dyk ned i forskningsemnerne om 'Pharmacoresponse in genetic generalized epilepsy: a genome-wide association study'. Sammen danner de et unikt fingeraftryk.

Citationsformater